The role of the oxygen of the benzopyran substituent of ⌬ 9 -tetrahydrocannabinol in defining affinity for brain cannabinoid (CB 1 ) receptors is not well understood; however, it is known that opening the pyran ring can result in either increased potency and affinity, as in CP 55,940 [(Ϫ)-cis-3-[2-hydroxy-4(1,1-dimethyl-heptyl)phenyl]-trans-4-(3-hydroxy-propyl)cyclohexanol], or in an inactive cannabinoid, as in cannabidiol. In the present study, a series of bicyclic resorcinols that resemble cannabidiol were synthesized and tested in vitro and in vivo. Analysis of the structure-activity relationships of these analogs revealed several structural features that were important for maintaining CB 1 receptor recognition and in vivo activity, including the presence of a branched lipophilic side chain and free phenols as well as substitution of a cyclohexane as the second ring of these bicyclic cannabinoids. Many of these analogs exhibited CB 2 selectivity, particularly the dimethoxyresorcinol analogs, and this selectivity was enhanced by longer side chain lengths. Hence, unlike cannabidiol, these resorcinol derivatives had good affinity for CB 1 and/or CB 2 receptors as well as potent in vivo activity. These results suggest that the resorcinol series represent a novel template for the development of CB 2 -selective cannabinoid agonists that have the potential to offer insights into similarities and differences between structural requirements for receptor recognition at CB 1 and CB 2 receptors.
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At least five distinct classes of cannabinoids have been identified: traditional tricyclic tetrahydrocannabinols [e.g., ⌬ 9 -tetrahydrocannabinol (THC)], synthetic bicyclic cannabinoids (e.g., CP 55,940; Little et al., 1988) , aminoalkylindoles (e.g., WIN 55,212; D'Ambra et al., 1992) , endocannabinoids (e.g., anandamide; Devane et al., 1992) , and pyrazole antagonists (e.g., SR141716A; Rinaldi-Carmona et al., 1994) . Although the chemical structures of these cannabinoids differ markedly, all of them contain at least one oxygen that is hypothesized to be involved in the binding of these drugs to brain cannabinoid (CB 1 ) receptors. ⌬ 9 -THC, the primary psychoactive constituent of the marijuana plant, and other tetrahydrocannabinols contain two oxygens: a phenolic hydroxyl at position 1 and an oxygen in a pyran ring on the opposite side of the molecule (Fig. 1) . The phenolic hydroxyl group at position 1 interacts with the CB 1 receptor through hydrogen bonding with a lysine residue (Song and Bonner, 1996) . The role of the oxygen of the benzopyran substituent of ⌬ 9 -THC is less clear; however, it is known that opening the pyran ring (as in CP 55,940) does not eliminate binding or in vivo activity (Little et al., 1988) . Furthermore, in the absence of a phenolic hydroxyl, as in 1-deoxy analogs of ⌬ 8 -THC, orientation of the cannabinoid molecule with respect to the CB 1 receptor may be inverted, and the pyran oxygen may substitute as a substrate for hydrogen bonding with Lys 192 (Huffman et al., 1996 (Huffman et al., , 1999 .
In contrast to the high binding affinity of CP 55,940 and other similar pyran ring open analogs, the natural product cannabidiol is also a pyran ring open compound, but it does not bind to CB 1 or CB 2 receptors nor does it have a cannabinoid profile of effects in vivo. Even the 1Ј,1Ј-dimethylheptyl analog of cannabidiol binds very poorly to the CB 1 receptor (R. K. Razdan, unpublished observations). This intriguing feature of cannabidiol prompted us to examine the structureactivity relationship of resorcinol derivatives, which could be considered as cannabidiol analogs.
After our work on the resorcinol series was initiated, Hanuš et al. (1999) published the synthesis and activity of HU-308, a dimethoxyresorcinol derivative that is a CB 2 -selective agonist. The transmembrane regions of CB 2 receptors (areas involved in ligand recognition) exhibit 68% homology with those of CB 1 receptors (Munro et al., 1993) . reported a high positive correlation (r ϭ 0.82) between binding affinities at these two cannabinoid receptors for cannabinoids in various classes. Given these findings, it is not surprising that some of the structural features of the tetrahydrocannabinols that enhance affinity for CB 1 receptors also increase binding to CB 2 receptors. For example, addition of a 1Ј,1Ј-dimethyl group to the lipophilic C3 side chain of ⌬ 8 -THC results in higher affinities for both types of cannabinoid receptors compared with a nonbranched chain of identical length . Several previous studies have explored the role of oxygen in CB 2 binding. Synthesis of a series of ⌬ 8 -THC analogs in which the phenolic hydroxyl at position 1 was removed (deoxy-⌬ 8 -THC analogs) or replaced with a methoxyl resulted in analogs with selectivity for CB 2 receptors (Gareau et al., 1996; Huffman et al., 1996 Huffman et al., , 1999 . Incorporation of an oxygen into a fourth ring attached at C1 also increased CB 2 selectivity, suggesting possible differences in the interaction of oxygen in the binding pockets of CB 1 and CB 2 receptors (Reggio et al., 1997) . In the present study, we examined structure-activity relationships of a series of bicyclic resorcinols in which the core chemical structure contained two hydroxyl substituents positioned with a single intervening carbon on a benzene ring. For most of the bicyclic resorcinols presented here, the second cyclic substituent is attached at the intermediate carbon.
Materials and Methods
Subjects. Male Institute for Cancer Research (ICR) mice (25-32 g), obtained from Harlan (Indianapolis, IN), were housed in groups of five. All animals were kept in a temperature-controlled (20 -22°C) environment with a 12-h light/dark cycle (lights on at 7 AM). Separate mice were used for testing each dose of each experimental compound in the in vivo behavioral procedures. Brain tissue for binding studies was obtained from male Sprague-Dawley rats (150 -200 g) purchased from Harlan.
Apparatus. Measurement of spontaneous activity in mice occurred in standard activity chambers interfaced with a Digiscan animal activity monitor (Omnitech Electronics, Inc., Columbus, OH). A standard tail-flick apparatus and a digital thermometer (Fisher Scientific, Pittsburgh, PA) were used to measure antinociception and rectal temperature, respectively.
Compounds. Resorcinols were synthesized in our laboratories (Organix, Inc., Woburn, MA) according to the procedure specified below and were suspended in a vehicle of absolute ethanol, Emulphor-620 (Rhone-Poulenc, Inc., Princeton, NJ), and saline in a ratio of 1:1:18. Experimental compounds were administered to the mice i.v. in the tail vein at a volume of 0.1 ml/10 g.
Analogs O-1376 and O-1532 listed in Table 1 were synthesized as previously described (Mahadevan et al., 2000) . Analog O-1601 was synthesized from 1-deoxy-9-carbomethoxy cannabinol dimethylheptyl analog (Mahadevan et al., 2000) by lithium/liquid ammonia reduction as described for the preparation of O-1376. The compounds listed in Tables 2 and 3 were prepared using a three-step sequence (Fig. 2) . The 2-lithio derivative of 1,3-dimethoxy-5-(1Ј,1Ј-dimethylheptyl)resorcinol was prepared using n-BuLi/hexane in THF (step 1). It was condensed with the appropriate ketone to give the tertiary alcohol (step 2), which upon treatment with trifluoroacetic acid/ Et 3 SiH gave the dimethoxy precursors (step 3). Demethylation with BBr 3 /CH 2 Cl 2 gave the target compounds (Crocker et al., 1999) . The general procedure is illustrated in Fig. 2 and described below.
To a solution of the resorcinol (5 mmol) in 25 ml of dry THF was added a 2.5 M solution of n-BuLi in hexane (5.5 mmol) at 0°C with stirring in N 2 . After additional stirring for 1 h at 0°C, a solution of the ketone (7.5 mmol) in 3 ml of dry THF was added all at once. The solution was stirred for 0.5 h at 0°C and then for 18 h at 23°C. The jpet.aspetjournals.org
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reaction was worked up by the addition of saturated NH 4 Cl solution and extracted with ether. After washing (H 2 O) and drying (Na 2 SO 4 ), the solvent was evaporated to give the crude tertiary alcohol, which was used as such in the subsequent reaction. A solution of the tertiary alcohol (5 mmol) in 10 ml of dry CH 2 Cl 2 was treated with CF 3 COOH (27.5 mmol) followed by Et 3 SiH (12.5 mmol). The solution was stirred in N 2 for 1 h or more (followed by TLC) and then quenched by the addition of saturated NaHCO 3 solution. The organic layer was separated and after washing (H 2 O) and drying gave the crude dimethoxy precursor of the target compound. This material was used as such for the demethylation step. Treatment of the dimethoxy precursor as a solution in dry CH 2 Cl 2 at 0°C with three equivalents of 1 N BBr 3 solution in CH 2 Cl 2 , using the standard procedure and workup, gave the crude target compound, which was purified by chromatography, generally using hexane/ethyl acetate mixtures. In the case of O-1662 (Table 2) , the corresponding tertiary alcohol, upon treatment with CF 3 COOH/Et 3 SiH, gave the unsaturated compound (dehydrated but not reduced), which on catalytic reduction (PtO 2 /C/H 2 ) in acetic acid gave the desired dimethoxy precursor. The final compound was purified by chromatography using a 5% Et 3 NH 2 /EtOAc mixture. The unsaturated analog O-1423 (Table 2 ) was prepared by treatment of the corresponding tertiary alcohol with CF 3 COOH alone in CH 2 Cl 2 , followed by demethylation. In Table 3 , compounds O-1797A and O-1798B were diastereomeric mixtures and showed as two distinct spots in TLC, which were separated by column chromatography on silica gel and eluting with hexane/ethyl acetate mixtures (10:1 to 5:1). O-1657 was a sample of the mixture of diastereomers O-1797A and O-1798B. The dimethoxy and O-1967B from a diastereomeric mixture was undertaken similarly, by eluting with hexane followed by 99% hexane/1% ethyl acetate mixture. Epoxidation of O-2114 followed by NaBH 4 reduction gave the target compound O-2122. In the preparation of O-2090, the corresponding diethoxyresorcinol derivative of step 1 was used in place of the 2-lithio derivative of 1,3-dimethoxy-5-(1Ј,1Ј-dimethylheptyl)resorcinol. All compounds showed appropriate 1 H NMR profiles (Jeol Eclipse 300 MHz; Jeol USA, Inc., Peabody, MA) and were characterized on the basis of their 1 H NMR profiles, TLC, and elemental analyses. The general profile of resorcinols (Tables 2 and 3) (Tables 4 and 5) showed an additional peak at ␦, 3.85 region (s, 6H) for the methoxyl groups and the multiplet for the benzylic methine at ␦, 3.4 to 3.2 was absent.
Mouse Behavioral Procedures. Prior to testing in the behavioral procedures, mice were acclimated to the experimental setting 
SA, suppression of spontaneous activity; RT, rectal temperature; TF, tail flick. a This dose (mol/kg) produced Ͼ50% inhibition and was the lowest dose tested.
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(ambient temperature 22-24°C) overnight. Preinjection control values were determined for rectal temperature and tail-flick latency (in seconds). Five min after i.v. injection with an experimental compound or vehicle, mice were placed in individual activity chambers, and spontaneous activity was measured for 10 min. Activity was measured as total number of interruptions of 16 photocell beams per chamber during the 10-min test and expressed as percent inhibition of activity of the vehicle group. Tail-flick latency was measured at 20 min postinjection. Maximum latency of 10 s was used. Antinociception was calculated as the percent maximal possible effect {%MPE ϭ [(test-control latency)/(10-control)] ϫ 100}. Control latencies typically ranged from 1.5 to 4.0 s. At 30 min postinjection, rectal temperature was measured. This value was expressed as the difference between control temperature (before injection) and temperatures following drug administration (⌬ o C). Different mice (n ϭ 5-6 per dose) were tested for each dose of each compound. Each mouse was tested in each of the three procedures.
CB 1 Binding Procedure. The methods used for tissue preparation and binding have been described previously (Compton et al., 1993) and are similar to those described by Devane et al. (1988) . All assays, as described briefly below, were performed in triplicate, and the results represent the combined data from three to six individual experiments.
Following decapitation and rapid removal of the brain, whole brain was homogenized and centrifuged. The resulting pellet was termed P 1 . The supernatant was saved and combined with the two subsequent supernatants obtained from washing the P 1 pellet. The combined supernatant fractions were centrifuged, resulting in the P 2 pellet. After further incubation and centrifuging, this pellet was resuspended in assay buffer to a protein concentration of approximately 2 mg/ml. The membrane preparation was quickly frozen in a bath solution of dry ice and 2-methylbutane (Sigma-Aldrich, St. Louis, MO), then stored at Ϫ80°C for no more than 2 weeks. Prior to performing a binding assay, an aliquot of frozen membrane was rapidly thawed, and protein values were determined by the method of Bradford (1976) .
Binding was initiated by the addition of 150 g of P 2 membrane to test tubes containing 1 nM [
3 H]CP 55,940 (79 Ci/mmol) and a sufficient quantity of buffer to bring the total incubation volume to 1 ml. Nonspecific binding was determined by the addition of 1 M unlabeled CP 55,940. Following incubation at 30°C for 1 h, binding was terminated by addition of ice-cold buffer and vacuum filtration through pretreated filters in a 12-well sampling manifold (Millipore Corp., Bedford, MA). After washing, filters were placed into plastic scintillation vials (Packard Instrument Co., Inc., Downers Grove, IL) and shaken. The quantity of radioactivity present was determined by liquid scintillation spectrometry. CB 2 Binding Procedure. Human CB 2 cDNA was provided by Dr. Sean Munro (MRC Laboratory of Molecular Biology, Cambridge, England) and was expressed in Chinese hamster ovary cells as previously described . Briefly, transfected CB 2 Chinese hamster ovary cell lines were maintained in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) to maintain selective pressure of stable transformants and 10% fetal clone II (Hyclone Laboratories, Inc., Logan, UT) plus 0.3 to 0.5 mg/ml G418 (to maintain selective pressure) under 5% CO 2 at 37°C. When confluent, cells were harvested with 1 mM EDTA in phosphate-buffered saline and centrifuged at 1000g for 5 min at 4°C. The supernatant was saved, and the P 1 pellet was resuspended in centrifugation buffer. Homogenization and centrifugation were repeated twice, and the combined supernatant fractions were centrifuged at 40,000g for 30 min at 4°C. The P 2 pellet was resuspended in centrifugation buffer 2 (50 mM Tris HCl, 1 mM EDTA, and 3 mM MgCl 2 , pH 7.4) to a protein concentration of approximately 2 mg/ml. Protein concentrations were determined by the method of Bradford (1976) using Bio-Rad protein assay (Bio-Rad, Hercules, CA) and bovine serum albumin standards (fatty acid free; Sigma-Aldrich). The membrane preparation was divided into amounts that were convenient for binding assays, frozen rapidly in dry ice, and stored at Ϫ80°C.
Binding was initiated by the addition of 50 g of quickly thawed P 2 membranes to test tubes containing [ 3 H]CP 55,940 (final reaction concentration, 0.5 nM), an appropriate concentration of unlabeled CP 55,940 or test compound, and sufficient quantity of assay buffer (50 mM Tris-HCl, 1 mM EDTA, 3 mM MgCl 2 , and 5 mg/ml bovine serum albumin, pH 7.4) to bring the total incubation volume to 0.5 ml. 
Cannabinoid Resorcinols 683
at ASPET Journals on April 10, 2017 jpet.aspetjournals.org from 50 to 10,000 pM. Nonspecific binding was determined by the addition of 1 M unlabeled CP 55,940. CP 55,940 and all cannabinoid analogs were prepared by suspension in assay buffer from 1 mg/ml ethanolic stock without evaporation of the ethanol (final concentration, no more than 0.4%). In competition studies, analog concentrations ranged from 0.1 nM to 10 M. After incubation at 30°C for 1 h, binding was terminated by the addition of 2 ml of ice-cold wash buffer (50 mM Tris-HCl and 1 mg/ml bovine serum albumin) and vacuum filtration through pretreated filters in a 12-well sampling manifold (Millipore). Reaction vessels were washed once with 2 ml of ice-cold wash buffer. Filters were placed into 7-ml plastic scintillation vials (RPI Corp., Mount Prospect, IL) with 4 ml of Budget-Solve (RPI Corp.). After shaking for 30 min, the radioactivity present was determined by liquid scintillation spectrometry. Three reaction vessels were used for each drug concentration in each assay.
The results represent the combined data of three independent experiments. All assays were performed in siliconized test tubes, which were prepared by air drying (12 h) inverted borosilicate tubes after two rinses with a 0.1% solution of AquaSil (Pierce Chemical, Rockford, IL). The GF/C glass-fiber filters (2.4 cm; Baxter, McGaw Park, IL) were pretreated in a 0.1% solution of pH 7.4 polyethylenimine (Sigma-Aldrich) for at least 6 h. Data Analysis. Based on data obtained from numerous previous studies with cannabinoids, maximal cannabinoid effects in each procedure were estimated as follows: 90% inhibition of spontaneous activity, 100% MPE in the tail-flick procedure, and Ϫ6°C change in rectal temperature. ED 50 was defined as the dose at which halfmaximal effect occurred. For compounds that produced one or more cannabinoid effect, ED 50 was calculated separately using leastsquares linear regression on the linear part of the dose-effect curve for each measure in the mouse tetrad, plotted against log 10 transformation of the dose. For the purposes of potency comparison, potencies were expressed as millimoles per kilogram.
Pearson product-moment correlation coefficients (with associated 
Results
The CB 1 and CB 2 binding affinities for substituted biphenyl analogs are shown in Table 1 . These compounds contain a phenolic hydroxyl and lipophilic side chain in the same orientation as in cannabinol. In addition, the pyran oxygen is absent, and the analogs have substituents in the phenyl ring (ring C) of cannabinol. Two of the analogs (O-1376 and O-1601) have a dimethylheptyl side chain; each possess good CB 1 and CB 2 binding affinities and in vivo activity. O-1601, the more potent of the two active compounds, had a hydroxymethyl group in the phenyl ring. This substitution increased CB 1 affinity and in vivo potencies compared with O-1376 but did not affect affinity for CB 2 receptors. A similar effect was observed in the cannabinol series, where the substitution of a hydroxymethyl group for a methyl at C-9 in cannabinol increased binding affinity and potency (Mahadevan et al., 2000) . Shortening the side chain of O-1376 to dimethylbutyl (O-1532) markedly decreased affinity for both receptors and resulted in loss of in vivo activity. Table 2 presents binding and in vivo data for a series of two jpet.aspetjournals.org cyclic ring-substituted-5-dimethylheptyl resorcinols. Manipulation of the size of the cyclic structure attached at position 2 of the resorcinol ring resulted in changes in binding affinities and potencies. Substitution of a cyclopentane ring (O-1424) resulted in moderate affinity for the CB 1 receptor, with excellent affinity for the CB 2 receptor. Although this compound was active in all three in vivo assays, potency was relatively poor. In addition, potencies across the measures were not equal; i.e., potency for reducing spontaneous activity was approximately half that for producing antinociceptive and hypothermic effects. Increasing ring size to a cyclohexane (O-1422), cycloheptane (O-1656), or adamantyl (O-1660) improved affinity 5-to 14-fold for both cannabinoid receptors and greatly increased potencies in vivo. Substitution of a sulfur for a carbon in a cyclohexane ring (O-1425) decreased CB 1 affinity by 14-fold and CB 2 affinity by 8-fold (compared with O-1422) as well as reducing in vivo potencies. Similarly, sulfur substitution in a cyclopentane ring (O-1661) also attenuated binding to both cannabinoid receptors. When a methylated nitrogen (O-1662) was inserted into the cyclohexane ring in the same position as the sulfur of O-1425, binding to CB 1 receptors did not occur. In addition, CB 2 binding was drastically decreased, and the compound was not fully active in vivo. In contrast, placing a double bond in the cyclohexane ring (O-1423) decreased affinities and potencies, but the compound remained active. However, moving the lipophilic side chain of O-1422 from C-5 to C-4 and replacing the dimethylheptyl with an n-hexyl chain (O-2010) produced a 865-fold decrease in CB 1 affinity and a loss of activity in vivo. Table 3 shows results of tests with cyclohexane-substituted resorcinols in which the position of the substituent at the cyclohexane ring attached to the core resorcinol was varied. All compounds were diastereomeric mixtures. All of these analogs had high (K i ϭ 2 nM) to moderate (K i ϭ 144 nM) affinity for CB 1 receptors and were CB 2 -selective (K i range ϭ 0.3-13 nM). Methylation at the 2-position of the cyclohexane ring (O-1658) did not dramatically alter affinity for either cannabinoid receptor or in vivo potencies compared with the corresponding cannabinoid with a nonmethylated cyclohexane (O-1422 in Table 2 ). Moving the methyl to position 4 of the cyclohexane ring (O-1659) decreased affinity for both cannabinoid receptors by about 5-fold and produced an even greater decrease (11-to 24-fold) in potencies in vivo. Substituting a phenyl group for the methyl at this same position (O-1663) resulted in 2-to 3-fold decreases in CB 2 and CB 1 affinities, respectively, and a loss of activity in vivo. In the next five analogs shown in Table 3 , the methyl was attached at position 3 of the cyclohexane ring. O-1657 exhibited CB 1 and CB 2 affinities that were similar to those of O-1658; however, the profiles of in vivo potencies differed. Whereas the two analogs showed approximately equal potencies in suppressing spontaneous activity, O-1658 was twice as potent in producing antinociception and three times as potent in reducing body temperature. As described under Materials and Methods, compound O-1657 was separated into two distinct entities, which were designated O-1797A and O-1798B. These analogs were still mixtures. Affinities of O-1797A and O-1798B were two to three times greater than those of O-1657. Although potencies of these isomers for suppression of locomotor activity and hypothermia were not notably different from those of O-1657, antinociceptive potencies were reduced by about half. The 3S isomer of this series (O-1826) showed decreased affinity for CB 1 receptors compared with O-1657; however, affinity for CB 2 receptors was identical for both compounds. Not surprisingly given its decreased CB 1 affinity, O-1826 was less potent than O-1657 in vivo. Substitution of a dimethylbutyl for the dimethylheptyl side chain at C5 of the resorcinol component (O-1890) decreased affinities for both cannabinoid receptors. This compound was active in vivo, although potency was notably low for all measures. In contrast, addition of a gem-dimethyl group at the 3-position of the cyclohexane ring, with retention of the dimethylheptyl side chain of the resorcinol component (O-1871), resulted in the best CB 1 and CB 2 affinities of this series. Given its higher CB 1 binding affinity, in vivo potencies for this compound were lower than expected, although the lack of pharmacokinetics assessments tempers this conclusion somewhat.
To develop CB 2 -selective ligands, we examined cyclic ringsubstituted dimethoxyresorcinols. The CB 1 and CB 2 binding affinities of these analogs are shown in Tables 4 and 5 . Although most of the compounds shown in Tables 4 and 5 possessed a dimethylheptyl side chain, all had poor CB 1 affinity; hence, they were not tested in vivo. The bicyclic structure of O-1999 (Table 4 ) was almost identical to that of O-1657 (Table 3) , an analog with good CB 1 and CB 2 affinities and potent in vivo effects. Both compounds had a dimethylheptyl side chain attached to the 5-position of a resorcinol core that was attached at position 2 to a cyclohexane ring. Each compound had a methyl group at the 3-position of the cyclohexane ring. The major structural difference between the two compounds was that O-1999 was a dimethoxy derivative of the resorcinol O-1657. This structural change from a phenol to a methoxy derivative resulted in complete loss of affinity for CB 1 receptors and an almost 600-fold reduction in affinity for CB 2 receptors. Similarly, the other analogs that were dimethoxy derivatives of the corresponding resorcinols had poor affinity for CB 1 receptors (K i ranged from 1716 to Ͼ 10,000) regardless of the cyclic ring substitution at position 2. In contrast, CB 2 binding affinities for some of these analogs remained high, as described in more detail below. Table 4 presents binding data for two cyclic ring-substituted dimethoxy-resorcinol-dimethylheptyl analogs that contain at least one oxygen inserted into or attached to the nonresorcinol cyclohexane ring. Compared with O-1999, which did not contain an oxygen in the cyclohexane ring, conversion of the cyclohexane ring to a pyran ring (O-1964) decreased CB 2 affinity almost 2-fold without effect on CB 1 binding. Further addition of a double bond at position 3 of the pyran ring resulted in O-1965, which did not bind to either cannabinoid receptor. In contrast, the introduction of a tertiary hydroxyl group at C-4 of the pyran ring (O-1962) increased CB 2 affinity by 3-fold. Adding additional oxygens, such as a ketol group attached at C-4 to the point of attachment of the dimethoxyresorcinol substituent (O-2092), also increased CB 2 affinity whereas adding an oxygen as an epoxide (O-2122) decreased it. The presence of a ketone group at C-4 of the cyclohexane ring and having unsaturation in the ring (O-2114) resulted in a compound with poor affinity for either cannabinoid receptor; however, if a tertiary hydroxyl group was added at the site of dimethoxyresorcinol attachment (O-2115), CB 2 affinity improved. Retention of the tertiary hydroxyl, methylation at position 5, and the presence of a ketone at position 3 of the cyclohexane ring increased affinity for both receptors and resulted in a compound (O-2123) with the best CB 2 affinity (K i ϭ 125 nM) in this series. Table 5 shows CB 1 and CB 2 affinities for two cyclic ringsubstituted dimethoxy-resorcinol-dimethylheptyl analogs in which the ring size and the position of the methyl or hydroxyl substituent on the cyclohexane ring are varied. The first analog (O-2072) contains one hydroxyl attached to the cyclohexane at the same position at which the resorcinol core is attached. This compound is CB 2 -selective. Although it had poor affinity for CB 1 receptors, it bound with moderate affinity to CB 2 receptors. Introduction of a methyl substituent in the 3-position of the cyclohexane ring gave a diastereomeric mixture from which two distinct entities were separated by careful chromatography. These analogs (O-1966A and O-1967B) were still mixtures. This substitution resulted in a 5-fold increase in affinity for CB 2 receptors with continued poor affinity for CB 1 receptors. However, one of these isomers (O-1966A) showed the best CB 2 selectivity (225-fold) in the series and had high binding affinity for the CB 2 receptor (K i ϭ 22.5 nM). Addition of an extra hydroxyl group to the cyclohexane ring (O-2121) reduced both selectivity and binding affinity for the CB 2 receptor comparable with those obtained with O-1967B. Removal of the methyl at position 3 and addition of a hydroxyl at position 4 resulted in two diastereomeric mixtures that could be separated, which were designated as O-2116A and O-2117B. Both of these isomers had poor affinity for CB 1 receptors, but although the B isomer also had poor affinity for CB 2 receptors, the A isomer bound to CB 2 receptors with moderate affinity. Multiple regression analysis of binding affinity (Y ϭ log CB 1 K i ) and potency for each mouse measure (X 1-3 ϭ log ED 50 in mmol/kg) confirmed that overall potency at producing the characteristic profile of cannabinoid effects was significantly correlated with binding affinity at CB 1 receptors [r ϭ 0.78; F(3,13) ϭ 6.9; p ϭ 0.005] for all active cannabinoids. Individual correlations between log K i and log potency for each measure were 0.78, 0.74, and 0.75 for hypomobility, antinociception, and hypothermia, respectively (p Ͻ 0.05 for all three correlations). Furthermore, CB 1 binding affinity was highly correlated with CB 2 binding affinity (r ϭ 0.92, p Ͻ 0.05) for all compounds for which both binding affinities could be calculated (i.e., K i Ͻ 10,000). Scatterplots for each regression line are presented in Fig. 3 .
Discussion
The lack of CB 1 binding affinity of cannabidiol compared with other pyran ring open analogs such as CP 55,940 prompted us to examine the structure-activity relationships of resorcinol derivatives for cannabinoid activity. Our results show that many of the structural changes that affect CB 1 receptor recognition and activation in traditional cannabinoids similarly alter binding and activity in this resorcinol series. Previous research has shown that the length and branching of a lipophilic substituent is important for CB 1 receptor recognition in all of the major cannabinoid agonist classes, including tetrahydrocannabinols and bicyclic cannabinoids (Compton et al., 1993) , indole-derived cannabinoids (Wiley et al., 1998) , and anandamides (Ryan et al., 1997; Seltzman et al., 1997) . In the tricyclic and bicyclic series, a 1Ј,1Ј-dimethylheptyl side chain is optimal (Compton et al., 1993) and is contained in most of the resorcinols presented here. Reducing the length of this substituent resulted in a concomitant elimination or decrease in CB 1 receptor recognition, as occurs in other cannabinoid series with similar structural manipulations (see references above).
Other structural features affecting CB 1 receptor recognition and activation in this series are related to the size, saturation, substitution, and methylation of the second nonresorcinol ring. In most tricyclic and bicyclic cannabinoids, the ring corresponding to the nonresorcinol ring in the current series is a cyclohexane. In the resorcinol series, reducing this size to a cyclopentane decreases CB 1 affinity and potency whereas increasing it to a cycloheptane has little effect. Similar modifications of other cannabinoids have not been reported; however, degree of saturation of, as well as the position of the double bond in the cyclohexane ring of tricyclic and bicyclic cannabinoids and in the polyolefin loop of the anandamides, has been shown to affect CB 1 receptor recognition and activity. In the resorcinol series, introduction of a single double bond (O-1423) within the ring decreased CB 1 affinity and potency to the same extent as did a reduction in the size of the ring to a cyclopentane. Greatest affinity and potency within the anandamides is achieved with four double bonds, with greater or lesser saturation resulting in a reduction in CB 1 binding and/or in vivo activity (Adams et al., 1995; 
